• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)

PRODUCT FILTERS

REGION

102
21
15
14
13

COUNTRY

15
4
2
2
2

PRICE

542
564
611
727

PUBLISHED

4
7
49
727

PRODUCT TYPE

487
230
10

Women's Health

Women are increasingly attractive to pharmaceuticals company. From adolescence to old age they come into contact with the medical services far more than men, and this gives pharmaceutical companies the opportunity to target women as a distinct customer group characterized by brand loyalty. Business opportunities are also provided by the emerging countries, where women are increasingly empowered to access reproductive and other health services.

Browse Research and Markets’ Women’s Health category to identify investment, business development and partnership opportunities across a variety of issues such as contraception, pregnancy, female infertility, dysmenorrheal, menopausal disorders, ovarian disease, vaginal atrophy, and more. Monitor the latest drug trials, enhance your clinical knowledge and explore specific markets with our reports, books, and subscriptions.

Leading players featured in our publications include Wyeth, Schering, Johnson & Johnson, and more. Show Less
Read more

PRODUCT TITLE

Vagifem (Postmenopausal Vaginal Atrophy) - Forecast and Market Analysis to 2022

Vagifem (Postmenopausal Vaginal Atrophy) - Forecast and Market Analysis to 2022 Summary Although the postmenopausal vaginal atrophy (PVA) market has experienced anemic growth over the past decade,...

July 2013
FROM

Premarin (Postmenopausal Vaginal Atrophy) - Forecast and Market Analysis to 2022

Premarin (Postmenopausal Vaginal Atrophy) - Forecast and Market Analysis to 2022 Summary Although the postmenopausal vaginal atrophy (PVA) market has experienced anemic growth over the past decade,...

July 2013
FROM

PharmaPoint: Postmenopausal Vaginal Atrophy - Spain Drug Forecast and Market Analysis to 2022

PharmaPoint: Postmenopausal Vaginal Atrophy - Spain Drug Forecast and Market Analysis to 2022 Summary Although the postmenopausal vaginal atrophy (PVA) market has experienced anemic growth over the...

July 2013
FROM

Estring (Postmenopausal Vaginal Atrophy) - Forecast and Market Analysis to 2022

Estring (Postmenopausal Vaginal Atrophy) - Forecast and Market Analysis to 2022 Summary Although the postmenopausal vaginal atrophy (PVA) market has experienced anemic growth over the past decade,...

July 2013
FROM

PharmaPoint: Postmenopausal Vaginal Atrophy - France Drug Forecast and Market Analysis to 2022

PharmaPoint: Postmenopausal Vaginal Atrophy - France Drug Forecast and Market Analysis to 2022 Summary Although the postmenopausal vaginal atrophy (PVA) market has experienced anemic growth over the...

July 2013
FROM

PharmaPoint: Postmenopausal Vaginal Atrophy - Japan Drug Forecast and Market Analysis to 2022

PharmaPoint: Postmenopausal Vaginal Atrophy - Japan Drug Forecast and Market Analysis to 2022 Summary Although the postmenopausal vaginal atrophy (PVA) market has experienced anemic growth over the...

July 2013
FROM

PharmaPoint: Postmenopausal Vaginal Atrophy - Germany Drug Forecast and Market Analysis to 2022

PharmaPoint: Postmenopausal Vaginal Atrophy - Germany Drug Forecast and Market Analysis to 2022 Summary Although the postmenopausal vaginal atrophy (PVA) market has experienced anemic growth over...

July 2013
FROM

PharmaPoint: Postmenopausal Vaginal Atrophy - US Drug Forecast And Market Analysis To 2022

PharmaPoint: Postmenopausal Vaginal Atrophy - US Drug Forecast And Market Analysis To 2022 Summary Although the postmenopausal vaginal atrophy (PVA) market has experienced anemic growth over the past...

July 2013
FROM

PharmaPoint: Postmenopausal Vaginal Atrophy - Italy Drug Forecast and Market Analysis to 2022

PharmaPoint: Postmenopausal Vaginal Atrophy - Italy Drug Forecast and Market Analysis to 2022 Summary Although the postmenopausal vaginal atrophy (PVA) market has experienced anemic growth over the...

July 2013
FROM

PharmaPoint: Postmenopausal Vaginal Atrophy - Current and Future Players

PharmaPoint: Postmenopausal Vaginal Atrophy - Current and Future Players Summary GlobalData has released its pharma report, “PharmaPoint: Postmenopausal Vaginal Atrophy - Current and Future Players”....

July 2013
FROM

Vasomotor Symptoms of Menopause - Pipeline Review, H1 2013

Vasomotor Symptoms of Menopause - Pipeline Review, H1 2013 Summary 'Vasomotor Symptoms of Menopause - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline....

June 2013
FROM

Premature Labor (Tocolysis) - Pipeline Review, H1 2013

Premature Labor (Tocolysis) - Pipeline Review, H1 2013 Summary 'Premature Labor (Tocolysis) - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report...

June 2013
FROM

Acute Inflammation - Pipeline Review, H1 2013

Acute Inflammation – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Acute Inflammation - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This...

May 2013
FROM

Ovarian Disease - Pipeline Review, H1 2013

Ovarian Disease – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Ovarian Disease - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report...

May 2013
FROM

Premenstrual Syndrome - Pipeline Review, H1 2013

Premenstrual Syndrome – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Premenstrual Syndrome - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline....

May 2013
FROM
Competitor Analysis: Human Papilloma Virus (HPV) Vaccines & Therapeutics Competitor Analysis: Human Papilloma Virus (HPV) Vaccines & Therapeutics - Product Thumbnail Image

Competitor Analysis: Human Papilloma Virus (HPV) Vaccines & Therapeutics

The Competitive Intelligence Report Human Papilloma Virus (HPV) Vaccines & Therapeutics as of May 2013 provides a competitor analysis in the product portfolios and development pipelines of novel vaccines...

May 2013
FROM
Female Hypoactive Sexual Desire Disorder - Pipeline Review, H1 2013 Female Hypoactive Sexual Desire Disorder - Pipeline Review, H1 2013 - Product Thumbnail Image

Female Hypoactive Sexual Desire Disorder - Pipeline Review, H1 2013

Female Hypoactive Sexual Desire Disorder – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Female Hypoactive Sexual Desire Disorder - Pipeline Review, H1 2013', provides an overview of...

April 2013
FROM

EpiCast Report: Postmenopausal Vaginal Atrophy - Epidemiology Forecast to 2022

EpiCast Report: Postmenopausal Vaginal Atrophy - Epidemiology Forecast to 2022 The urogenital tract, specifically the vagina, urethra, bladder, trigone of the bladder, and pelvic floor muscles, contains...

March 2013
FROM
Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H1 2013 Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H1 2013 - Product Thumbnail Image

Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H1 2013

Vaginal Atrophy (Atrophic Vaginitis) – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H1 2013', provides an overview of the indication’s...

March 2013
FROM
Menopausal Hot Flashes - Pipeline Review, H1 2013 Menopausal Hot Flashes - Pipeline Review, H1 2013 - Product Thumbnail Image

Menopausal Hot Flashes - Pipeline Review, H1 2013

Menopausal Hot Flashes – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Menopausal Hot Flashes - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline....

March 2013
FROM
Loading Indicator

Our Clients

Our clients' logos